Sagimet Biosciences Inc.

Last updated September 27, 2026
Favorite this organization

Organization details

Legal name
Sagimet Biosciences Inc.
Former names
3-V Biosciences, Inc.
Ownership
Public
Status
Active
SIC code
2834 — Pharmaceutical Preparations
Jurisdiction of incorporation
Delaware
Headquarters city
Foster City
Headquarters state / province
California
Headquarters country
United States
Fiscal year end
December
Ticker symbol
SGMT
Primary stock exchange
Nasdaq

Identifiers

SEC CIK
0001400118
EIN
20-5991472

Board of directors

Follow this board

Chief executives

David Happel · President & CEO
Dates unknown

Director election results

Annual meeting of June 12, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.

Board connections

7 of this board's directors also sit on 20 other boards.

Network of Sagimet Biosciences Inc.'s board connections Ardelyx Inc. Ardelyx Inc. Latigo Biotherapeutics Inc. Latigo Biotherapeutics... Arcus Biosciences Inc. Arcus Biosciences Inc. ArriVent BioPharma Inc. ArriVent BioPharma Inc... Atara Biotherapeutics Inc. Atara Biotherapeutics... BioMarin Pharmaceutical Inc. BioMarin Pharmaceutica... Century Therapeutics Inc. Century Therapeutics I... Damora Therapeutics Inc. Damora Therapeutics In... Kardigan Inc. Kardigan Inc. Kyverna Therapeutics Inc. Kyverna Therapeutics I... Mirum Pharmaceuticals Inc. Mirum Pharmaceuticals... Novavax Inc. Novavax Inc. Odyssey Therapeutics Inc. Odyssey Therapeutics I... OnKure Therapeutics Inc. OnKure Therapeutics In... Opus Genetics Inc. Opus Genetics Inc. Progyny Inc. Progyny Inc. Beth C. Seidenberg Beth C. Seidenberg Jennifer Jarrett Jennifer Jarrett Merdad Parsey Merdad Parsey Paul W. Hoelscher Paul W. Hoelscher Richard J. Rodgers Richard J. Rodgers Timothy P. Walbert Timothy P. Walbert Sagimet Biosciences Inc.
Shared director Other board Same sector +4 more in the list below

Insider trades

All notable trades →

From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.

Bought, last 12 months
$0
0 purchases by 0 insiders
Sold, last 12 months
$4,907,434
10 sales by 5 insiders
Date Insider Transaction Shares Price Value
Aug 14, 2026 George Kemble Director Option exercise +326,618 $6.36 $2,077,290
Aug 14, 2026 George Kemble Director Option exercise +24,369 $6.36 $154,987
Aug 14, 2026 George Kemble Director Open-market sale −350,987 $10.23 $3,591,580
Aug 11, 2026 George Kemble Director Option exercise +9,751 $6.36 $62,016
Aug 11, 2026 George Kemble Director Option exercise +10,455 $6.36 $66,494
Aug 11, 2026 George Kemble Director Open-market sale −20,206 $9.95 $201,147
Jul 20, 2026 David Happel Director, Officer (President & CEO) Open-market sale −64,051 $7.76 $497,068
Jul 20, 2026 George Kemble Director Open-market sale −18,844 $7.46 $140,529
Jul 20, 2026 Rozek Elizabeth Officer (Chief Legal & Admin. Officer) Open-market sale −10,545 $7.76 $81,832
Feb 19, 2026 Rozek Elizabeth Officer (Chief Legal & Admin. Officer) Grant or award +44,000 — —
Feb 19, 2026 Eduardo Bruno Martins Officer (Chief Medical Officer) Grant or award +44,000 — —
Feb 19, 2026 David Happel Director, Officer (President & CEO) Grant or award +128,000 — —
Feb 19, 2026 Chauche Thierry Officer (Chief Financial Officer) Grant or award +44,000 — —
Feb 10, 2026 David Happel Director, Officer (President & CEO) Open-market sale −12,101 $5.36 $64,861
Feb 10, 2026 Chauche Thierry Officer (Chief Financial Officer) Open-market sale −1,312 $5.36 $7,032

Reviews (0)

Sign in to write a review.

No reviews yet. Be the first to write one.

We use cookies to run this site and, with your permission, to measure traffic and support the affiliate links that help fund it.